23.04.2013 • NewsClariantpigmentsunder construction

Clariant Invests for Asian Pigments Customers

Clariant, a producer of specialty chemicals, will build a new pigment preparations plant in Indonesia in a series of investments in China, India and Indonesia.The company is investing approximately CHF 8 million to enhance its capabilities in the region.

The investments include the construction of a new pigment preparations plant at Clariant's Tangerang site in Indonesia that will double capacity. Production is scheduled to commence in September 2013. Clariant is also finalizing the feasibility for expanding the capacity at its Azo pigments and pigment preparations plants in Roha, India by 50%. Clariant's marketing and sales organization in China, India and Indonesia will be doubled throughout 2013.

Additionally, Technical service capabilities in China will be strengthened by increasing the number of technical professionals in Clariant's STAR application laboratory in Shanghai by nearly double.

Finally, Clariant will also expand its development capabilities in Roha (India), Shanghai and DaGang (China) to provide a faster response to requests for product development tailored to the needs of the local markets. The addition of Regional Product Managers for both Azo pigments and pigment preparations will strengthen this support.

 

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.